Milk Thistle for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Milk Thistle for Health & Longevity

Created on 08/14/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

Milk thistle is a seed extract used for liver and blood-sugar support. The strongest signal is a modest drop in blood sugar in type 2 diabetes. Fatty-liver enzyme effects remain mixed and uncertain. Alcohol-related and viral disease showed no survival benefit. Risks are mild; product quality varies widely. A low-risk metabolic add-on, not a proven longevity drug. (Full Review)

Protocol

Legalon-style standardized extract
140 mg silymarin three times daily
420 mg/day Legalon-style; 700 mg three times daily is a NASH trial regimen, not a default
Phytosome / phosphatidylcholine complex
about 120 mg silybin twice daily
Phosphatidylcholine (Siliphos-type) raises absorption versus ordinary extract
Time of day
Split with meals
Morning, midday, and evening; 1–8 hour half-life makes once-daily dosing a poor match
Time to effect
Glucose changes
4–12 weeks
When they occur; fasting glucose and HbA1c
Enzyme changes
4–12 weeks
When they occur; ALT and AST in fatty liver
NASH fibrosis signal
48 weeks
Measured at this point in biopsy-proven NASH

Benefits

Contraindications
  • Known allergy to milk thistle or other Asteraceae plants (ragweed, daisy, chrysanthemum, marigold), including prior anaphylaxis
  • Pregnancy and lactation, except in a supervised research setting
  • Hormone-sensitive breast, uterine, or ovarian cancer, active endometriosis, or fibroids
  • Concurrent simeprevir, or unstable anticoagulation with a labile INR, until a monitoring plan exists
  • Child-Pugh Class C (severe) decompensated cirrhosis when the goal is disease modification
    •
Key Interactions
  • CYP2C9 substrates (warfarin, diazepam)
  • P-gp substrates (talinolol, some other export-pump drugs)
  • Diabetes medications (metformin, insulin, sulfonylureas, SGLT2 inhibitors such as empagliflozin)
  • Raloxifene (Evista)
  • Sirolimus (Rapamune)
  • Tamoxifen and other hormone-modulating drugs
  • Acetaminophen / other hepatotoxic over-the-counter drugs
  • Additive liver-support supplements (N-acetylcysteine, berberine, curcumin, vitamin E)
  • Alcohol
    •

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal symptoms; Asteraceae-family allergic reactions
    •
  • Low: Additive glucose lowering with diabetes drugs; pharmacokinetic interactions via P-gp and CYP2C9; headache
    •
  • Speculative: Estrogen-receptor modulation in hormone-sensitive conditions; product contamination and label inaccuracy
    •

Monitoring

Marker Target Why
ALT 10–25 U/L Tracks hepatocellular injury
AST 10–25 U/L Second liver-injury marker
GGT <20–30 U/L Bile/oxidative and alcohol stress
Fasting glucose 75–90 mg/dL Detects additive lowering and benefit
HbA1c 4.8–5.3% Three-month glucose load
Fasting insulin / HOMA-IR Insulin 3–8 μIU/mL; HOMA-IR <2 Insulin-resistance context
LDL-C / triglycerides LDL-C <70–100 mg/dL; triglycerides <100 mg/dL Cardiometabolic response
INR Per anticoagulation target Warfarin interaction watch
Ferritin 50–150 ng/mL (context-specific) Iron overload vs inflammation

Cadence: Baseline; 4 weeks; 12 weeks; then every 3–6 months while the extract continues. Recheck INR 3–7 days after start or stop if on warfarin

Qualitative Assessment

  • Gastrointestinal comfort (bloating, stool change) in the first two weeks
  • Daytime energy and post-meal fullness if fatty liver was symptomatic
  • Home glucose traces in people on diabetes drugs
  • New itch, rash, or breathing symptoms (allergy)
  • Alcohol intake honesty
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.